Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer

Zhang,Xie; Zhang,Xuesong; Sun,Beilei; Lu,Hongna; Wang,Danping; Yuan,Xiaogang; Huang,Zhigang

doi:10.3892/ol.2014.2410

Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer

Authors:
- Xie Zhang
- Xuesong Zhang
- Beilei Sun
- Hongna Lu
- Danping Wang
- Xiaogang Yuan
- Zhigang Huang
View Affiliations

Affiliations: Department of Gastroenterology, Ningbo Medical Treatment Center, Li Huili Hospital, Ningbo, Zhejiang 315040, P.R. China, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, P.R. China
Published online on: August 4, 2014 https://doi.org/10.3892/ol.2014.2410
Pages: 1745-1750

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is one of the most frequently diagnosed malignancies in East Asia, particularly in China, and remains the second leading cause of cancer‑associated mortality worldwide. However, no effective plasma biomarkers have been identified for the diagnosis of patients with GC. The aim of this study was to investigate the DNA methylation status of the ring finger protein 180 (RNF180), secreted frizzled‑related protein 2 (SFRP2) and death‑associated protein kinase 1 (DAPK1) genes in the plasma samples of 57 GC patients and 42 control individuals with no malignant disease, and to evaluate the clinical utility of these makers. A significantly higher level of methylation was observed in the plasma DNA of GC patients when compared with that of controls for the three genes investigated (RNF180, 57.89% vs. 23.81%; DAPK1, 49.12% vs. 28.57%; and SFRP2, 71.93% vs. 42.86%). No association was identified between the DAPK1 or SFRP2 methylation level in the plasma DNA and the clinicopathological parameters of patients. Notably, RNF180 methylation was found to positively correlate with tumor size (P=0.018), histological type (P=0.025), TNM stage (P=0.002), lymph node metastasis (P=0.008) and distant metastasis (P=0.018). Overall, 50 cancer patients (87.72%) exhibited methylation of at least one of the three markers, while 26 normal subjects presented methylation in plasma DNA [specificity, 38.1%; odds ratio (OR), 4.4]. The combined use of RNF180 and SFRP2 as methylation markers appeared to be the most preferable predictor with regard to predictive power and cost‑performance (OR, 5.57; P=0.0002). The results of the present study indicate that aberrant promoter methylation of genes in the plasma may be detected in a substantial proportion of GC patients and thus, these genes must be evaluated in the screening and surveillance of GC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
2	Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol. 12:354–362. 2006.
3	Shi Y and Zhou Y: The role of surgery in the treatment of gastric cancer. J Surg Oncol. 101:687–692. 2010.
4	Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:646–650. 1977.
5	Hanash SM, Baik CS and Kallioniemi O: Emerging molecular biomarkers - blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 8:142–150. 2011.
6	Kohler C, Barekati Z, Radpour R and Zhong XY: Cell-free DNA in the circulation as a potential cancer biomarker. Anticancer Res. 31:2623–2628. 2011.
7	Sharma VK, Vouros P and Glick J: Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids. Int J Mass Spectrom. 304:172–183. 2011.
8	Schwarzenbach H, Hoon DS and Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 11:426–437. 2011.
9	Jones PA and Baylin SB: The epigenomics of cancer. Cell. 128:683–692. 2007.
10	Cheung KF, Lam CN, Wu K, et al: Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer. Cancer. 118:947–959. 2012.
11	Qu Y, Dang S and Hou P: Gene methylation in gastric cancer. Clin Chim Acta. 424:53–65. 2013.
12	Lee TL, Leung WK, Chan MW, et al: Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res. 8:1761–1766. 2002.
13	Cheng YY, Yu J, Wong YP, et al: Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer. 97:895–901. 2007.
14	Martinez-Glez V, Franco-Hernandez C, Gonzalez-Gomez P, et al: DAPK1 promoter hypermethylation in brain metastases and peripheral blood. Neoplasma. 54:123–126. 2007.
15	Ben Ayed-Guerfali D, Benhaj K, Khabir A, et al: Hypermethylation of tumor-related genes in Tunisian patients with gastric carcinoma: clinical and biological significance. J Surg Oncol. 103:687–694. 2011.
16	Washington K: 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 17:3077–3079. 2010.
17	Xiong HL, Liu XQ, Sun AH, He Y, Li J and Xia Y: Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer. Asian Pac J Cancer Prev. 14:3139–3142. 2013.
18	Wani M, Afroze D, Makhdoomi M, et al: Promoter methylation status of DNA repair gene (hMLH1) in gastric carcinoma patients of the Kashmir valley. Asian Pac J Cancer Prev. 13:4177–4181. 2012.
19	Mir MR, Shabir N, Wani KA, et al: Association between p16, hMLH1 and E-cadherin promoter hypermethylation and intake of local hot salted tea and sun-dried foods in Kashmiris with gastric tumors. Asian Pac J Cancer Prev. 13:181–186. 2012.
20	Abbaszadegan MR, Moaven O, Sima HR, et al: p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J Gastroenterol. 14:2055–2060. 2008.
21	Lu XX, Yu JL, Ying LS, et al: Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer. 118:5507–5017. 2012.
22	Kang GH, Lee S, Cho NY, et al: DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest. 88:161–170. 2008.
23	Li WQ, Pan KF, Zhang Y, et al: RUNX3 methylation and expression associated with advanced precancerous gastric lesions in a Chinese population. Carcinogenesis. 32:406–410. 2011.
24	Sugita H, Iida S, Inokuchi M, et al: Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol Rep. 25:513–518. 2011.
25	Yao D, Shi J, Shi B, et al: Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta. 413:787–794. 2012.
26	Ksiaa F, Ziadi S, Amara K, Korbi S and Trimeche M: Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma. Clin Chim Acta. 404:128–133. 2009.
27	Hiraki M, Kitajima Y, Koga Y, et al: Aberrant gene methylation is a biomarker for the detection of cancer cells in peritoneal wash samples from advanced gastric cancer patients. Ann Surg Oncol. 18:3013–3019. 2011.
28	Banzai C, Nishino K, Quan J, Yoshihara K, Sekine M, Yahata T and Tanaka K; Gynecological Cancer Registry of Niigata. Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma. Int J Clin Oncol. 19:127–132. 2014.
29	Kilinc D, Ozdemir O, Ozdemir S, Korgali E, Koksal B, Uslu A and Gultekin YE: Alterations in promoter methylation status of tumor suppressor HIC1, SFRP2, and DAPK1 genes in prostate carcinomas. DNA Cell Biol. 31:826–832. 2012.
30	Ogawa M, Mizugishi K, Ishiguro A, et al: Rines/RNF180, a novel RING finger gene-encoded product, is a membrane-bound ubiquitin ligase. Genes Cells. 13:397–409. 2008.
31	Tamura G: Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol. 12:192–198. 2006.
32	Kinoshita T, Nomoto S, Kodera Y, Koike M, Fujiwara M and Nakao A: Decreased expression and aberrant hypermethylation of the SFRP genes in human gastric cancer. Hepatogastroenterology. 58:1051–1056. 2011.
33	Nojima M, Suzuki H, Toyota M, et al: Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene. 26:4699–4713. 2007.